
Last updated: 2026-10-14 11:57:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Septerna, Inc. (SEPN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $36.39, with a market capitalisation of $1.75B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.55 to $51.10. This page covers its latest market performance, valuation, price trends and company information.
$1.75B | |
$36.46 | |
$51.10 | |
$4.17 | |
$36.42 | |
235.00 | |
384.87K | |
-- | |
$51.10 | |
$17.55 | |
-- | |
-- |
Septerna, Inc. (SEPN) is trading at $36.39 in pre-market trading as of 2026-10-14 11:19:00, down 0.08% ($0.03) from the previous close of $36.42
Pre-market trading shows how investors are pricing SEPN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Septerna, Inc. (SEPN) moved from $37.87 to $36.39, representing a decline of 3.92% ($1.48).
The stock traded between $34.66 and $41.76 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 511.51 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 56.1%
SEPN is currently trading at $36.39, placing it 56.1% of the way from its 52-week low of $17.55 to its 52-week high of $51.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Septerna, Inc. (SEPN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.